Wedbush Maintains Outperform on Werewolf Therapeutics, Lowers Price Target to $6

Benzinga · 5d ago
Wedbush analyst Robert Driscoll maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Outperform and lowers the price target from $8 to $6.